US FDA says all doses of Lilly’s weight-loss and diabetes drug now available

(Reuters) – All doses of Eli Lilly (NYSE:)’s weight-loss drug Zepbound and diabetes drug Mounjaro are now available, the U.S. Food and Drug Administration’s updated shortage list showed on Friday.

Lilly’s Mounjaro has been on the U.S. FDA’s shortage list since late 2022, while Zepbound was added to the list in April this year.